Management

管理

• 批准号: 7575465
• 负责人: TIMOTHY A CROSS
• 金额: $ 8.28万
• 依托单位: FLORIDA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-20 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7575465
• 关键词: Advisory Committees; Annual Reports; Charge; Code; Collaborations; Committee Members; Communication; Communication Tools; Consultations; Databases; Development; Discipline; Drug Delivery Systems; Engineering; Escherichia coli; Essential Genes; Financial Support; Florida; Frequencies; Funding Mechanisms; Goals; Grant; Image; Individual; Institutes; Institution; Laboratories; Membrane Proteins; Methods; Mutagenesis; Mutation; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Participant; Pharmacologic Substance; Postdoctoral Fellow; Protein NMR Spectroscopy; Radio; Reporting; Research; Research Personnel; Research Project Grants; Screening procedure; Site; Technology; Universities; Work; assay development; base; design; drug development; experience; magnetic field; meetings; multidisciplinary; mycobacterial; novel; payment; programs; protein expression; protein structure; skills; solid state nuclear magnetic resonance; symposium; tuberculosis drugs; web site

The PI will have overall and final responsibility for the scientific management of the Program and will act in consultation with the Project Leaders (PLs) and Core Leaders (CLs) who will form an Executive Committee. The PI has considerable experience in the management of large research and user facility programs, as well as the management of a previous P01 grant. Florida State University, as the primary applicant institution will have the responsibility for establishing and maintaining the appropriate administrative and financial oversight. Corresponding administrative and financial support exists at each of the collaborating institutions. Team institutions will receive subcontracts from Florida State University. Subcontract payments will be approved by the PI following review of an annual work plan submitted by the investigators with the Core or Project leaders approval. Subcontracts will be reviewed annually at one of the biannual face-to-face meetings of the Team and Executive Committee (composed of Project and Core Leaders). The PI will have the responsibility following such consultation and additional discussion with External Advisory Committee members to discuss with the appropriate Program officer at NIAID any adjustment in the amount of the various subcontracts to maximize the Program's progress towards its aims. In addition to the face-to-face meeting the Executive committee will meet every month by conference call (video with powerpoint when beneficial), The Project and Core Leaders will also meet regularly by conference call with their individual project and core teams and minutes will be submitted to the PI. The Program will also establish an External Advisory Committee that will have diverse expertise in the TB and drug development arenas. In choosing committee members it will be our intent to expand the base of expertise, especially in the direction of potential drug development, so that we can charge the committee to assess our progress towards the goal of characterizing potential drug targets. We expect each member of the committee to meet annually with the Program in one of our face-to-face meetings. Since there are two of these we hope to have several committee members at each meeting. They will be asked to submit a brief report to the PI following each meeting. These reports will be part of the Annual Report to NIAID. The PI has full responsibility for reporting to NIAID on scientific progress and goals. The PLs and CLs have the responsibility to submit an annual report to the PI two weeks before the NIAID due date and following the second annual Program meeting. Florida State University has responsibility for reporting annually on the financial status of the Program

PI将对项目的科学管理负有全面和最终的责任，并将采取行动 与项目领导者 (PL) 和核心领导者 (CL) 协商，他们将组成执行官 委员会。 PI在管理大型研究和用户设施方面拥有丰富的经验 计划，以及之前 P01 拨款的管理。佛罗里达州立大学作为主要 申请机构将有责任建立和维持适当的行政管理 和财务监督。每个合作机构均提供相应的行政和财务支持 机构。 团队机构将获得佛罗里达州立大学的分包合同。分包合同付款将 在审查研究者与核心或核心人员提交的年度工作计划后，由 PI 批准 项目领导批准。分包合同将在每年两次的面对面审查中进行审查 团队和执行委员会（由项目和核心领导者组成）会议。 PI 将有 与外部咨询委员会进行此类磋商和额外讨论后的责任 成员与 NIAID 的相应项目官员讨论对金额的任何调整 各种分包合同，以最大限度地推进该计划实现其目标。除了面对面的交流之外 执行委员会将每月通过电话会议召开会议（视频与幻灯片，当 有益），项目和核心领导人还将通过电话会议定期与他们的个人会面 项目和核心团队以及会议记录将提交给 PI。 该计划还将设立一个外部咨询委员会，该委员会将拥有结核病方面的多种专业知识 和药物开发领域。在选择委员会成员时，我们的目的是扩大委员会的基础 专业知识，特别是潜在药物开发方向的专业知识，以便我们可以责成委员会 评估我们在描述潜在药物靶点的目标方面取得的进展。我们期望每一位成员 委员会每年在一次面对面会议上与该计划会面。由于有两个 我们希望每次会议都有几位委员会成员。他们将被要求提交一份简短的 每次会议后向 PI 报告。这些报告将成为向 NIAID 提交的年度报告的一部分。 PI 全权负责向 NIAID 报告科学进展和目标。 PL 和 CL 有责任在 NIAID 截止日期前两周向 PI 提交年度报告，并且 第二次年度计划会议之后。佛罗里达州立大学负责报告 每年报告该计划的财务状况